Literature DB >> 22113824

Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study.

Luisa Costa1, Francesco Caso, Lanfranco D'Elia, Mariangela Atteno, Rosario Peluso, Antonio Del Puente, Pasquale Strazzullo, Raffaele Scarpa.   

Abstract

The objective of the study was the evaluation of arterial stiffness, a cardiovascular risk factor, in patients with psoriatic arthritis (PsA). Twenty PsA patients classified on the basis of the CASPAR criteria (M/W, 14/6; mean age, 38.6 years; range, 22-53), attending our out-patient clinic, and 20 healthy control subjects (M/W, 14/6; mean age, 38.7 years; range, 22-53) matched for age, weight, height and with similar cardiometabolic profile entered the study. An exclusion criterion was the presence of known cardiovascular risk factors. Central hemodynamic parameters and aortic pulse wave velocity (aPWV) were assessed non-invasively by a SphygmoCor device. A significantly higher aPWV was recorded in PsA patients when compared to controls. The difference remained statistically significant after adjustment for age, weight, height, heart rate (HR) and central mean pressure (mean±SE; PsA, 8.3 ± 0.2 versus control, 6.8 ± 0.2 m/s; p < 0.0001). Among PsA patients, aPWV was related to known duration of disease (r = 0.63; p = 0.003). This result was confirmed after adjustment for the main confounders (β = 0.011; p = 0.013). These results support the concept of psoriatic disease as a systemic condition involving not only the skin, joints and gastrointestinal tract but also arterial vessels. The involvement of the vascular system indicates the presence of pathogenetic mechanisms that could accelerate the atherosclerotic process in this condition.

Entities:  

Mesh:

Year:  2011        PMID: 22113824     DOI: 10.1007/s10067-011-1892-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Authors:  Stephane Laurent; John Cockcroft; Luc Van Bortel; Pierre Boutouyrie; Cristina Giannattasio; Daniel Hayoz; Bruno Pannier; Charalambos Vlachopoulos; Ian Wilkinson; Harry Struijker-Boudier
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

2.  Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population.

Authors:  Tine Willum-Hansen; Jan A Staessen; Christian Torp-Pedersen; Susanne Rasmussen; Lutgarde Thijs; Hans Ibsen; Jørgen Jeppesen
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

Review 3.  Psoriatic disease: concepts and implications.

Authors:  R Scarpa; G Altomare; A Marchesoni; N Balato; M Matucci Cerinic; T Lotti; I Olivieri; G A Vena; C Salvarani; G Valesini; A Giannetti
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-02-25       Impact factor: 6.166

4.  Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle.

Authors:  G W De Keulenaer; R W Alexander; M Ushio-Fukai; N Ishizaka; K K Griendling
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

5.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

6.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

Authors:  Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

Authors:  D D Gladman; V T Farewell; K Wong; J Husted
Journal:  Arthritis Rheum       Date:  1998-06

Review 8.  Pathogenesis of psoriatic arthritis.

Authors:  Allen P Anandarajah; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

9.  High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors.

Authors:  Carlos Gonzalez-Juanatey; Javier Llorca; Encarnacion Amigo-Diaz; Trinidad Dierssen; Javier Martin; Miguel A Gonzalez-Gay
Journal:  Arthritis Rheum       Date:  2007-08-15

10.  Psoriasis, psoriatic arthritis, or psoriatic disease?

Authors:  Raffaele Scarpa; Fabio Ayala; Nicola Caporaso; Ignazio Olivieri
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

View more
  37 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

3.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Arthur Kavanaugh; Philip Helliwell; Christopher T Ritchlin
Journal:  Rheumatol Ther       Date:  2016-02-29

Review 4.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

5.  Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".

Authors:  Matteo Megna; Anna Balato; Maddalena Napolitano; Lucia Gallo; Francesco Caso; Luisa Costa; Nicola Balato; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2018-04-11       Impact factor: 2.980

6.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

7.  Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.

Authors:  Luisa Costa; Ennio Lubrano; Roberta Ramonda; Maria Sole Chimenti; Maristella Vezzù; Fabio M Perrotta; Antonio Del Puente; Rosario Peluso; Paolo Bottiglieri; Mariagrazia Lorenzin; Flavia Sunzini; Md Abud Darda; Ugo Fiocco; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Francesco Caso
Journal:  Clin Rheumatol       Date:  2017-06-07       Impact factor: 2.980

8.  Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.

Authors:  Maddalena Napolitano; Luisa Costa; Francesco Caso; Matteo Megna; Raffaele Scarpa; Nicola Balato; Fabio Ayala; Anna Balato
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

9.  Extra-articular manifestations in psoriatic arthritis patients.

Authors:  Rosario Peluso; Salvatore Iervolino; Maria Vitiello; Vincenzo Bruner; Gelsy Lupoli; Matteo Nicola Dario Di Minno
Journal:  Clin Rheumatol       Date:  2014-05-08       Impact factor: 2.980

Review 10.  Biological therapies for spondyloarthritis.

Authors:  Vincenzo Bruner; Mariangela Atteno; Angelo Spanò; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-06       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.